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TUMOUR DORMANCY IN BREAST CANCER
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The review analyzes the recent evolution of two paradigms
related to the development of breast cancer metastases. The
continuous growth model is required to yield to an interrupted
growth model, the tantamount of which are episodes of
“tumour dormancy”. Primary tumour removal, usually
considered as intrinsically beneficial, proves to be able to
perturb metastatic homeostasis and to result, for some patients,
in the acceleration of metastatic cancer spread. Paradigm
evolution is supported by a growing body of findings from
experimental models and is required to explain breast cancer
recurrence dynamics for patients undergoing surgery without
or with adjuvant chemotherapy. 
Classical models that were proposed to explain breast
cancer metastasis dynamics after primary tumour removal
assumed the implicit hypothesis that tumours must always
grow. The concept of uninterrupted growth failed to explain
findings from both local and local plus distant recurrences. In
particular, the bimodal recurrence pattern, which presents an
early peak at the second year after surgery, a second peak at
about 5 years and a tapered plateau-like tail extending up to
15 years, should be explained. This pattern is independent of
the seeded organ, and may be observed in all metastatic sites.
On the contrary, a new dormancy-based model of metastasis
development was found to better fit clinical data. According
to this model, metastatic tumour may either continuously grow
or even sojourn in two dormant states, i.e. single cells and
avascular micrometastases, with orderly transitions between
these two dormant states eventually resulting in progressive
appearance of clinical metastases. Moreover, some
precipitating event at the time of primary tumour surgical
removal may have a triggering effect. In spite of a century of
investigations, the effects of primary tumour surgical removal
on metastases have practically been ignored by clinicians.
Single cells may be induced to proliferate via the conversion
of non-cycling G0 cells or by switching avascular micro-
metastatic foci to active angiogenesis. These processes occur
to different extent in pre- and post-menopausal patients. The
model found confirmation by the analysis of the recurrence
risk for patients receiving adjuvant CMF, where the recurrence
reduction occurred at specific, temporally separate recurrence
clusters at the first and third year, for both menopausal
statuses. 
The proposed dormancy-based metastasis development
model implies some kind of control on tumour growth from
the microenvironment, some kind of homeostatic effect upon
distant metastases. These concepts are poorly understandable
within the classical frame, where cancer is a genome-driven
disease, i.e. a cell-autonomous irreversible process and where
the tumour microenvironment is an idle bystander, sometimes
forced to provide factors supporting tumour progression.
However, all these views (epitheliocentric somatic mutation
paradigm, irreversibility of the neoplastic phenotype,
insignificant role of the microenvironment) have been
challenged by experimental evidence both in vitro and in vivo.
A new image of breast cancer is emerging. Cells that we label
“cancer cells” go on with their peculiar ability to have cross-
talk with the environment. This trait accounts for the
neoplastic behaviour, ranging from quiescence to open growth,
in different sites and/or at different times. Tumour dormancy
and the counterintuitive consequence of primary tumour
removal have a logical place in this context. The traditional
image of breast cancer is changing.
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Telomeres consist of protein complexes and repeated
‘TTAGGG’ double strand DNA sequences ended by a 3’
single strand DNA of the same sequence. Progressive telomere
shortening is observed in vitro upon cell divisions and with
ageing in vivo. At a critical telomere length, shortened
telomeres trigger a permanent growth arrest known as
replicative senescence. Telomerase is an RNA-dependent DNA
polymerase that extends telomeres by adding ‘TTAGGG’
repeats. It consists of a functional RNA component (hTR)
which serves as template and a catalytic protein (hTERT) with
reverse transcriptase activity. The expression of hTERT alone
is sufficient for the immortalisation of cells. Telomerase is
highly expressed in tumor cells but at very low level in most
somatic cells. These observations make the telomerase an
attractive target for anticancer strategies. One of these
strategies relies on the use of drug candidates able to stabilize
the particular telomere G-quadruplex DNA structures. The
stabilization of these structures makes the telomere
inaccessible for telomerase and thus inhibits telomerase
activity.
The effect of the hTERT transfection was first studied on
the proteome of human WI38 fibroblast cells (1). Then, the
proteome alteration response of hTERT transfected WI38 cells
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induced by the treatment of two G-quadruplexes ligands,
telomestatin and TMPyP4, was analyzed. Both compounds
can inhibit telomerase but have different selectivity for the
different G-quadruplexes structures. 
Proteome analysis of the treated cells reveals that TMPyP4
induces much more protein expression alterations than
telomestatin probably due to its poor selectivity. TMPyP4
induces especially a drastic down expression of the hnRNPs, a
modulation of the proteasome pathway, an apparent decrease
of the translation and an over expression of several molecular
chaperones. Telomestatin induces in particular an over
expression of the protein BCL2A1 which is involved in drug-
resistance of cancer cells and a probable increase of the
translation. Both treatments have a common effect particularly
on the molecular chaperone CCT (down expression), HSP90
alpha (over expression) and hnRNP D (down expression). The
protein HSP90 alpha is also over expressed in hTERT
transfected cells compared to parental cells. This protein is
already a promising anticancer target protein due to its central
role in oncogenesis and in telomerase activity regulation. 
1 Mazzucchelli et al: Proteome Science 6: 12, 2008.
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A major challenge in oncology is to develop more accurate
imaging assessments. The ADONIS Project intends to prove
the concept of using optoacoustic imaging with biologically
functionalized nanoparticles as an integrated biosensor based
imaging system for the production of specific and sensitive
data for accurate diagnosis of prostate cancer. This concept
involves using contrast agents which upon photoactivation
induce the local heating of their environment, generating
pressure waves that are detectable by piezoelectric transducers.
One of the main objectives of this project is to produce and
validate a versatile lab system composed of functionalized
nanoparticles for diagnosis of different superficial and
accessible cancers, e.g. prostate cancer. Gold nanorods have
been synthesized and functionalized with antibodies targeting
specific antigens on cancer cell lines. The foremost challenge
consists in synthesizing rod-like nanoparticles absorbing about
1064 nm, the spectral range where biological tissues absorb the
least. A wet chemical approach in solution, using surfactants
as dynamic template and silver nitrate as growth inhibitor, is
used for synthesis. Once the particles have been synthesized,
the surfactant is replaced by a biocompatible polymer for use in
in vitro tests. The polymer-coated nanoparticles are then
coupled with an antibody directed against the cancer cells to
guarantee the selective detection of the particles. 
Prostate Specific Membrane Antigen (PSMA), a
transmembrane protein considered as a suitable biomarker for
prostate cancer, was selected as the primary target.
Recognition and successful binding of the biosensor to PSMA
is demonstrated by various techniques using cell monolayers
and 3D cell cultures. PSMA localization on the LNCaP cell
membranes was identified by immunocytochemistry (HRP, Q-
Dots). Backscattered electron (BSE) microscopy and two-
photon luminescence imaging proved that the biosensor is
bound to the viable and fixed cells expressing PSMA. 
Gold particles attached to cancer cells serve as contrast
agents for optoacoustic detection. The concept of detecting
PSMA-expressing tumours using this integrated optoacoustic
biosensor system was confirmed on LNCaP spheroids (cell
aggregates) in gelatine phantoms. This system is currently
being tested on in vivo human tumour xenograft animal models
and in the future will be tested on human tumour biopsies.
6th Framework Programme of the European Commission,
STREP n˚ NMP4-CT-2005-016880.
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Background: Diffuse malignant peritoneal mesothelioma
(DMPM) is a rare and rapidly lethal neoplasm. In recent years,
the combination of cytoreductive surgery and hyperthermic
intraperitoneal chemotherapy (CRS+HIPEC) has resulted in a
significant survival improvement, as compared to historical
controls. Little is known about DMPM genetic and molecular
features. In the present study, we assessed new prognostic
indicators and therapeutic targets in a large series of DMPM
undergoing CRS+HIPEC. Methods: From a prospective data-
base of 86 cases, we selected 66 DMPM. Cases with well-
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